Astellas Pharma Inc.
Basic information
- Head office
- Tokyo
- Chief executive
- Naoki Okamura
- Capital
- 100,000,000,000 JPY (1,000 100 millionJPY)
- Employees (non-consolidated)
- 3,000 people
- Employees (consolidated)
- 14,000 people
- Start date
- 2005-04-01
- End date
Websites
Business
Related companies
Network
History
Fujisawa Pharmaceutical Industries, established in 1894.
Tomoyoshi Fujisawa founded Fujisawa Store in Osaka.
Yamanouchi Pharmaceutical, established in 1923.
Released camphor as a household insect repellent and deodorizer.
Kenji Yamanouchi founded Yamanouchi Pharmaceutical Merchants in Osaka, which was later renamed Yamanouchi Pharmaceutical Inc.
Renamed to Yamanouchi Pharmaceutical Inc. in 1940.
Founded Yamanouchi Pharmaceutical Merchants in 1940.
Kenji Yamanouchi founded Yamanouchi Pharmaceutical Merchants in Osaka.
Yamanouchi Pharmaceutical moved its headquarters to Tokyo.
Moved headquarters to Tokyo in 1942.
Moved headquarters to Tokyo in 1942.
Renamed Yamanouchi Pharmaceutical Merchants to Yamanouchi Pharmaceutical Inc.
Moved Yamanouchi Pharmaceutical Merchants' headquarters to Tokyo.
Renamed to Fujisawa Pharmaceutical Industries Inc.
Tomoyoshi Fujisawa founded Fujisawa Store in Osaka.
Completed Fujisawa Pharmaceutical Industries' Central Research Institute.
Yamanouchi Pharmaceutical launched the antibiotic josamycin.
Fujisawa Pharmaceutical Industries launched the injectable antibiotic cefamidine.
Fujisawa Pharmaceutical Industries established Fujisawa Pharmaceutical, Corp. in the United States.
Fujisawa Pharmaceutical Industries opened its first European office in London.
Yamanouchi Pharmaceutical launched the antihypertensive drug perdigine.
Completed Fujisawa Pharmaceutical Industries' Tsukuba Research Institute.
Yamanouchi Pharmaceutical launched the H2 receptor antagonist Gaster, now sold in over 100 countries.
Yamanouchi Pharmaceutical established Yamanouchi Ireland Co., Ltd. in Europe, its first overseas active ingredient manufacturing site.
Completed Yamanouchi Pharmaceutical's Tsukuba Research Institute.
Yamanouchi Pharmaceutical acquired the pharmaceutical division of Royal Hist Brokades in the Netherlands.
Fujisawa Pharmaceutical Industries established Fujisawa Europe GmbH in Germany.
Yamanouchi Pharmaceutical launched the urinary disorder improvement drug Harunair, now sold in over 90 countries.
Yamanouchi Pharmaceutical launched the urinary disorder improvement drug Harunair, now sold in over 90 countries; Fujisawa Pharmaceutical Industries launched the immunosuppressant Prograf, now sold in about 100 countries.
Yamanouchi Pharmaceutical established Shenyang Yamanouchi Pharmaceutical Co., Ltd. in China.
Fujisawa Pharmaceutical Industries reorganized its U.S. operations and established Fujisawa Healthcare, Inc.
Fujisawa Pharmaceutical Industries launched the atopic dermatitis treatment Protopick, now sold in about 60 countries.
Released the hypercholesterolemia treatment Lipitol.
Yamanouchi Pharmaceutical established Yamanouchi Pharma America Inc. in the United States as its own sales site.
Yamanouchi Pharmaceutical launched the overactive bladder treatment Beshicare in Europe, and it was also launched in the United States in 2005.
Yamanouchi Pharmaceutical launched the overactive bladder treatment Beshicare in Europe, and it was also launched in the United States in 2005; integrated the generic pharmaceutical businesses of both companies and established Zeparma.
Yamanouchi Pharmaceutical established Yamanouchi Ireland Co., Ltd. in Europe.
Yamanouchi Pharmaceutical established Shenyang Yamanouchi Pharmaceutical Co., Ltd. in China.
Fujisawa Pharmaceutical Industries reorganized its U.S. operations and established Fujisawa Healthcare, Inc.
Yamanouchi Pharmaceutical established Yamanouchi Pharma America Inc. in the United States.
The two companies integrated their generic pharmaceutical businesses and established Zeparma.
Integrated the generic pharmaceutical businesses of both companies and established Zeparma.
Astellas Pharma Inc. was founded through the merger of the former Yamanouchi Pharmaceutical and the former Fujisawa Pharmaceutical Industries.
Astellas Pharma was founded through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical Industries.
Astellas Pharma celebrated its 20th anniversary in April 2005.
Yamanouchi Pharmaceutical's urology and synthetic technologies merged with Fujisawa Pharmaceutical Industries' transplant, immunology, and fermentation technologies.
Established Fujisawa Pharmaceutical, Corp. in the United States.
Astellas was established in April 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical.
Founded in April 2005. Astellas was founded in April 2005 through the merger of Yamanouchi Pharmaceutical, established in 1923, and Fujisawa Pharmaceutical Industries, established in 1894. The strengths of Yamanouchi Pharmaceutical's urology and synthetic technologies and Fujisawa Pharmaceutical Industries' transplant, immunology, and fermentation technologies merged to form an optimal complementary partnership.
Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical Industries merged in April 2005, founding Astellas.
Astellas Pharma Inc. was founded through the merger of the former Yamanouchi Pharmaceutical and the former Fujisawa Pharmaceutical Industries.
Transferred Zeparma, a company engaged in generic pharmaceuticals, to Daiichi Sankyo Co., Ltd.
Released the quinolone oral synthetic antibacterial Geninack™ in Japan. Acquired the U.S. biotech venture Agensys.
Released the quinolone oral synthetic antibacterial Geninack™ in Japan. Acquired the U.S. biotech venture Agensys.
Acquired the U.S. pharmaceutical company OSI Pharmaceuticals.
Released the overactive bladder treatment Betanis™ in Japan. Signed the UN Global Compact.
Released the overactive bladder treatment Betanis™ in Japan. Signed the UN Global Compact.
Installed wind power at the Kerry plant in Ireland and started operation of a wood biomass boiler. Participated in a new public-private partnership for developing schistosomiasis treatment for preschool children. Launched the prostate cancer treatment XTANDI™ in the United States.
Installed wind power at the Kerry plant in Ireland and started operation of a wood biomass boiler. Participated in a new public-private partnership for developing schistosomiasis treatment for preschool children. Launched the prostate cancer treatment XTANDI™ in the United States.
In April 2025, Astellas celebrated its 20th anniversary as a company.
Astellas Pharma celebrated its 20th anniversary in April 2025. Astellas was founded in April 2005 through the merger of Yamanouchi Pharmaceutical, established in 1923, and Fujisawa Pharmaceutical Industries, established in 1894.
Astellas Pharma celebrated its 20th anniversary in April 2025.
Astellas Pharma celebrated its 20th anniversary in April 2025.
News
There is no news.
Public records
National Tax Agency basic information5010001034966
- Trade name
- アステラス製薬株式会社
- Trade name (kana)
- アステラスセイヤク
- Name in English
- Corporation type
- 301
- Address
- 〒103-0023 東京都中央区日本橋本町２丁目５番１号
- Postal code
- 1030023
- Prefecture code
- 13
- City code
- 102
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2023-12-14
- Change date
- 2022-04-01
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- 令和４年４月１日東京都中央区日本橋本町二丁目５番１号アステラスファーマテック株式会社（7010001139549）を合併令和４年４月１日東京都中央区日本橋本町二丁目５番１号アステラスグリーンサプライ株式会社（4010001092817）を合併
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 71
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 1866231
METI gBizINFO5010001034966
- Corporate number
- 5010001034966
- Trade name
- アステラス製薬株式会社
- Trade name (kana)
- アステラスセイヤク
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都中央区日本橋本町２丁目５番１号
- Postal code
- 1030023
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 中央区
- City code
- 102
- Street address
- 日本橋本町２丁目５番１号
- Organisation type
- 301
- Processing type
- 71
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 岡村 直樹
- Capital
- 103001000000
- Employees
- 4948
- Employees (male)
- 3182
- Employees (female)
- 1393
- Business summary
- 医薬品の製造・販売および輸出入
- Website URL
- http://www.astellas.com/jp/
- Year founded
- Business category
- E:製造業
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2023-12-14
- Key information
- 5010001034966